Skip to main content
Midas Edge

Catheter Precision, Inc.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

VTAK$0.15-0.7%Stored close · as of Oct 2, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

ITEM 6. EXHIBITS

Exhibit · Incorporated by Reference
NumberDescriptionFormFile No.ExhibitFiling Date
2.1* · Asset Purchase Agreement dated April 22, 2025 by and between the Company and Cardionomic (assignment for the benefit of creditors), LLC
3.1.1Amended and Restated Certificate of Incorporation of the Registrant.8-K001-386773.110/1/2018
3.1.2Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. (effective 11/16/20)8-K001-386773.111/17/2020
3.1.3Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. (effective 09/30/22)8-K001-386773.19/20/2022
3.1.3ACertificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. (filed 08/01/23, effective 08/17/23)8-K001-386773.18/4/2023
3.1.3BCertificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (filed 07/11/2024, effective 07/15/2024)8-K001-386773.17/12/2024
3.1.3CCertificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (effective 1/13/2025)10-K001-386773.13/31/2025
3.1.4Certificate of Designation of Series X Convertible Preferred Stock.8-K001-386773.11/13/2023
3.1.5Certificate of Designation of Series A Preferred Stock.8-K001-386773.21/13/2023
3.1.6Certificate of Designation of Series B Preferred Stock.8-K001-386773.15/13/2025
3.2.1Amended and Restated Bylaws of the Registrant.8-K001-386773.210/1/2018
3.2.2Amendment to Amended and Restated Bylaws of the Registrant.8-K001-386773.18/17/2022
4.1Specimen common stock certificate of the Registrant.S-1333-2261914.17/16/2018
4.10Form of Series B Warrant offered in February 2022.S-1/A333-2621954.92/3/2022
4.11Form of Series C Warrant issued in July 20228-K001-386774.17/22/2022
4.12Warrant Agency Agreement, dated February 8, 2022, by and between the Registrant and American Stock & Trust Company LLC.8-K001-386774.42/9/2022
4.12.1Amendment No. 1, dated July 22, 2022, to February 8, 2022 Warrant Agency Agreement by and between the Company and American Stock Transfer & Trust Company, LLC.10-Q001-386774.78/15/2022
4.17Form of Series I common stock Warrant issued September 20248-K001-386774.29/6/2024
4.18Form of Series J common stock Warrant issued September 20248-K001-386774.39/6/2024
4.20Form of Series K Warrant issued October 20248-K001-386774.110/25/2024
4.21Form of Placement Agent Warrant offered in October 20248-K/A001-386774.211/4/2024
4.22Form of Underwriters' Warrant offered in September 2024S-1333-2799304.176/26/2024
4.23Form of Warrant Agency Agreement dated as of September 3, 2024 entered into by and between the Registrant and Equiniti Trust Company, LLC8-K001-386774.59/6/2024
4.24Form of Series L Warrant offered in May 2025.8-K001-386774.15/13/2025
10.1* · Amendment to Investment Banking Agreement dated as of April 16, 2025 entered into by and between the Company and Ladenburg Thalmann & Co. Inc.
10.2At the Market Offering Agreement dated as of May 19, 2025 entered into by and between the Company and Ladenburg Thalmann & Co. Inc.8-K001-3867710.15/19/2025
10.3Securities Purchase Agreement dated May 12, 20258-K001-3867710.15/13/2025
10.4Registration Rights Agreement dated May 12, 20258-K001-3867710.25/13/2025
10.5Assignment Agreement dated May 12, 20258-K001-3867710.35/13/2025
10.6*Investment Banking Agreement dated February 11, 2025 entered into by and between the Company and Ladenburg Thalmann & Co. Inc.
31.1*Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*@Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*@Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*Cover Page Interactive Data File (embedded within the Inline XBRL document).
*Filed herewith.
@The information in this exhibit is furnished and deemed not filed with the Securities and Exchange Commission for purposes of section 18 of the Exchange Act of 1934, as amended (Exchange Act), and is not to be incorporated by reference into any filing of Catheter Precision, Inc. under the Securities Act of 1933, as amended (Securities Act), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.